Alex Philippidis

For the scientific enterprise, 2025 was marked by setbacks and challenges. But scientists are no strangers to adversity—the ability to overcome obstacles is built into our training. In turn, research labs across […]

Korro Bio saw its stock reach all-time lows on disappointing data for its lead pipeline candidate, while Intellia Therapeutics saw analyst downgrades on safety concerns despite releasing positive data for two of its key pipeline programs.

Eli Lilly will partner with Insilico Medicine on an artificial intelligence (AI)-based drug development collaboration that they said could generate “over $100 million” for the AI drug discovery company.

AI-based drug developer Recursion’s stock barely moved Wednesday, then dropped Thursday and Friday, after reporting mixed third quarter results, setting the stage for future pipeline announcements—and announcing a change at the top.

This week's episode features business news on uniQure, Recursion, and Roche along with a discussion on drug discovery improvements using AI.

South Rampart Pharma is working to develop an oral small molecule non-opioid pain treatment which has generated early positive clinical data as a therapy for acute and chronic pain, as well as preclinical studies in diabetic and chemotherapy neuropathy.

uniQure acknowledged that what it called “game changing” data in September showing significant slowing of Huntington’s disease (HD) progression in patients treated with its gene therapy candidate AMT-130 may not be enough to secure FDA approval.

The patient, a man in his early 80s with a high body mass index, was dosed with nex-z on September 30. Intellia learned of his condition approximately 24 days post-dosing, the company disclosed during a conference call with analysts held to discuss the dosing pauses.

Novo Nordisk has made an unsolicited, approximately up to $9 billion bid for Metsera—more than a month after Pfizer announced its intent to buy the company for up to $7.3 billion.

Recursion, Roche, and its Genentech subsidiary have unveiled a whole-genome map of specialized microglial immune cells that they plan to use toward revealing significant new targets in neurodegenerative diseases.